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The murine transmembrane glycoprotein CD83 is an important regulator for both thymic T cell maturation and peripheral T
cell responses. Recently, we reported that CD83 also has a function on B cells: Ubiquitous transgenic (Tg) expression of CD83
interfered with the immunoglobulin (Ig) response to infectious agents and to T cell dependent as well as T cell independent
model antigen immunization. Here we compare the function of CD83Tg B cells that overexpress CD83 and CD83 mutant
(CD83mu) B cells that display a drastically reduced CD83 expression. Correlating with CD83 expression, the basic as well as the
lipopolysaccharide (LPS) induced expression of the activation markers CD86 and MHC-II are significantly increased in CD83Tg B
cells and reciprocally decreased in CD83mu B cells. Wild-type B cells rapidly upregulate CD83 within three hours post BCR or
TLR engagement by de novo protein synthesis. The forced premature overexpression of CD83 on the CD83Tg B cells results in
reduced calcium signaling, reduced Ig secretion and a reciprocally increased IL-10 production upon in vitro activation. This
altered phenotype is mediated by CD83 expressed on the B cells themselves, since it is observed in the absence of accessory
cells. In line with this finding, purified CD83mu B cells displayed a reduced IL-10 production and slightly increased Ig secretion
upon LPS stimulation in vitro. Taken together, our data strongly suggest that CD83 is expressed by B cells upon activation and
contributes to the regulation of B cell function.
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Ig Secretion by CD83Tg B Cells. PLoS ONE 2(8): e755. doi:10.1371/journal.pone.0000755
INTRODUCTION
CD83 is a type I transmembrane glycoprotein, a member of the Ig
superfamily [1,2] and was initially described as a highly specific
marker for activated human dendritic cells (DC) in the peripheral
blood [3,4]. Murine CD83 displays 63% identity to human CD83
in the amino acid sequence and northern blot analysis revealed
expression predominantly in the brain and spleen [5] as well as in
activated bone marrow derived dendritic cells (BM-DC) [6].
The analysis of mouse strains deficient for CD83 [7,8] revealed
that thymic CD83 expression is crucial for the maturation of
double positive thymocytes to single CD4 positive T cells. CD83
2/
2 mice displayed a dramatically reduced amount of single positive
T helper cells in the thymus and in the periphery that were
restored to normal level by expression of CD83 on thymic
epithelial cells. In line with these results the thymic maturation in
the presence of ubiquitously expressed soluble CD83Ig fusion
protein led to the generation of CD4 positive T cells in normal
numbers but with an impaired function [9]. In addition to this
central role in the thymic selection of T helper cells there is
accumulating evidence suggesting a function for CD83 as an
immunological regulator of peripheral T cell responses. Culture in
the presence of either a soluble CD83Ig fusion protein or soluble
fragments of the extracellular CD83 domain inhibited lymphocyte
proliferation in human and murine systems in vitro [10–12].
Human cytomegalovirus (HCMV) infection induced the shedding
of naturally expressed CD83 by infected human DC and this
soluble CD83 again suppressed allogenic T cell proliferation [13].
Finally, the administration of recombinant human CD83 inhibited
the onset of experimental autoimmune encephalomyelitis (EAE)
and cured already induced disease in vivo [14].
The mechanism of CD83 mediated immune regulation and the
nature of the putative CD83 ligand however, still remain enigmatic
[15,16]. On the one hand human and murine DC upregulated
CD83 upon activation [3,4,6] and engagement of its putative ligand
by CD83 transfected APC increased human T cell activation [17]
[18], suggesting that CD83 represents a costimulatory receptor for T
cell activation like CD86 and CD80 [19]. On the other hand the
expression level of CD83 on DCdid not correlate with their capacity
to activate murine T cells as shown by three independent studies
employing CD83 deficient as well as CD83 overexpressing DC, thus
ruling out a non redundant costimulatory function for CD83 on DC
at least in the murine system [7,8,20].
Monitoring murine CD83 expression pattern and kinetics under
conditions of an ongoing Leishmania major (L. major)o rTrypanosoma
cruzi (T. cruzi) infection, we recently demonstrated surface expression
of CD83 predominantly on B cells. That CD83 plays an important
role on B cells was substantiated by the fact that the ubiquitous
transgenic expression of CD83 in vivo on the B cells themselves
stronglyinterferedwiththeproductionofL.majorand T.cruzispecific
Ig as well as with the humoral response to thymus dependent (TD)
and thymus independent (TI) model antigens [21].
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PLoS ONE | www.plosone.org 1 August 2007 | Issue 8 | e755Here we analyze the impact of CD83 expression on B cell
activation in vitro. We report that CD83 overexpression induced an
increased MHC-II and CD86 expression on CD83Tg B cells
whereas diminished CD83 expression on CD83mu B cells resulted
in a reciprocally reduced expression of these activation markers.
CD83 was rapidly upregulated by activated wild-type B cells
within three hours post BCR or TLR engagement. Premature
transgenic overexpression of CD83 on B cells at the beginning of
stimulation resulted in reduced calcium signaling as well as
reduced Ig secretion and reciprocally increased IL-10 production.
This phenotype was restricted to the B cell compartment since the
CD83Tg T cells displayed normal calcium signaling and pro-
liferation upon in vitro stimulation. Furthermore the altered
activation of CD83Tg B cells was mediated by CD83 expressed
on B cells themselves since it did not depend on the presence of
accessory cells. Although reduced CD83 expression did not alter
the response of CD83mu spleen cell cultures to LPS stimulation in
vitro, a reduction in IL-10 release together with a slight increase in
Ig production was observed in purified CD83mu B cell cultures.
Therefore our data strongly suggest that CD83, expressed on
activated B cells, plays a central role in the modulation of B cell
function.
METHODS
Mice and antibodies
All mouse strains employed were bred in the animal facilities of the
Bernhard-Nocht-Institute for tropical medicine or in the university
hospital Hamburg-Eppendorf (Hamburg, Germany) which are
registered by the Federal Health Authorities of the State of
Hamburg. Experiments employing mice described within this
manuscript are approved by ‘‘Amt fu ¨r Gesundheit und Verbrau-
cherschutz’’ as 32/05 and 20/07. The animal facilities and the
CD83Tg mice founder 2 and founder 1 were generated at the
Bernhard-Nocht-Institute [20], Ig HEL BCR transgenic mice
(IgHEL Tg) [22] were a kind gift of Prof. Dr. Christian Kurts,
(Universita ¨t Bonn, Germany). F1 generation of IgHELTg and
CD83Tg with C57BL/6 were bred at the Bernhard-Nocht-
Institute. CD83 mutant mice (CD83mu, termed LCD4.1 origi-
nally) [8] were a kind gift of Prof. Dr. Fred Ramsdell
(Zymogenetics, Seattly, WA). Monoclonal antibodies were
obtained from BD Pharmingen and Caltag Laboratories. The
mAb to mouse CD83 Michel-19 was generated at the Bernhard-
Nocht-Institute by immunizing rats with a CD83Ig fusion protein
[10]. The polyclonal rabbit antiserum to CD83 was generated at
the university hospital Hamburg-Eppendorf by gene gun DNA
immunization with murine CD83 full length cDNA.
Flow cytometry
The Fc receptors of 2610
5 spleen cells were blocked with mouse
serum (5% v/v) for 10 min on ice. Cells were stained with 1:100
dilutions of the indicated mAb for 20 min on ice and analyzed on
a Becton-Dickinson FACS-Calibur equipped with Cell Quest Pro
software. Ab and reagents used: FITC-labeled or biotinylated anti-
mouse CD83 clone Michel-19; FITC-labeled Rat IgG1, clone R3-
34; PE anti-mouse CD19, clone 1D3; PE anti-mouse MHC-II,
clone M5/114.15.2; Cy5 affinity purified goat anti-mouse IgM m-
chain specific; PE anti-mouse CD69, clone H1.2F3; PE anti-
mouse CD86, clone RMMP-2; PE anti-mouse CD80, clone
RMMP-1; FITC anti-mouse CD40, clone 3/23; biotinylated anti-
mouse CD138, clone 281-2. Cell death was measured employing
the Annexin-V-Fluostaining Kit (Roche, Mannheim, Germany),
according to the manufacturer `s recommendation.
In vitro stimulation of spleen and B cells for CD83
detection
Spleens were prepared from 6 to 10 week old female C57BL/6,
CD83Tg founder 1 and founder 2, CD83 negative littermate to
CD83Tg founder 1 and CD83mu mice. 2610
6 cells were cultured
in 2 ml RPMI 1640 medium supplemented with 10% fetal calf
serum, 20 mM Hepes and L-glutamine in 24well culture dishes.
LPS (10 mg/ml) or anti-BCR (clone 187.1; 1 mg/ml) with or
without IL-4 (20 ng/ml) were added. Cells were cultured at 37uC
and 5% CO2 and triple stained with biotinylated anti-CD83
followed by APC labeled-streptavidin, anti-CD19 FITC and anti-
CD69 PE at various time points. Untouched B cells were purified
from spleens by magnetic cell sorting employing the Pan B cell
isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions. Purity of the resulting
cell population was analyzed by FACS to be .98% (data not
shown). 2610
6 purified B cells were incubated with or without
10 mg/ml LPS in 24well culture dishes for 1h and 6h. Cells were
harvested and analyzed for CD83 expression by western blot.
CD83 specific western blot
2610
6 B cells were lysed in 50 ml lysis buffer (150 mM NaCl,
50 mM Tris pH 7,4, 1% CHAPS) supplemented with Complete
EDTA-free Protease inhibitor (Roche, Mannheim, Germany). For
deglycosylation 18 mg protein of each sample was denatured in
a total volume of 25 mlw i t h0 , 5ml 10% SDS for 10 min at 70uC.
Afterwards 2,5 ml 10% NP40 were added and samples were
incubated with 0,5 U N-Glycosidase F overnight. 12 mgp r o t e i n
were loaded in each slot and separated by SDS-Page on a 10–20%
PAA gradient gel (Anamed, Darmstadt, Germany) and blotted to an
Immobilon-P PVDF membrane (Millipore, Schwalbach, Germany).
CD83 was detected by incubating the blocked membrane with
a 1:10.000 fold dilution of the polyclonal rabbit anti-mouse CD83
serum, followed by incubation with a 1:2000 dilution of HRP
conjugated goat anti-rabbit immunoglobulin (Dako, Glostrup,
Denmark) and developed with ECL
TM Western Blotting Detection
Reagents (Amersham Biosciences, Buckinghamshire, England).
In vitro stimulation of spleen and B cells
Whole spleen cells or purified B cells (2610
5) derived from
C57BL/6, CD83Tg founder 1, CD83 negative littermates to
founder 1, CD83Tg founder 2, CD83mu, IgHELTg or IgHEL/
CD83 double Tg mice were stimulated with LPS (10 mg/ml) or
anti-CD3 (145-2C11, 1 mg/ml) in 0,2 ml RPMI 1640 medium
supplemented with 10% fetal calf serum, 20 mM Hepes and L-
glutamine in 96 well culture plates. Proliferation was measured by
the uptake of
3H-thymidine after 48h culture for additional 18h.
IL-10 in the supernatant was measured by standard sandwich
ELISA employing IL-10 DuoSet ELISA development kit (R&D
Systems, Wiesbaden, Germany) according to the manufacturer `s
instructions. Polyclonal Ig was measured in serial dilutions of the
culture supernatant after seven days by sandwich ELISA employ-
ing 1,25 mg/ml rabbit anti-mouse Ig (polyclonal serum: DAKO
#Z0259) as capture and 0.65 mg/ml peroxidase conjugated rabbit
anti-mouse Ig (purified fraction of polyclonal antiserum: DAKO #
P0260) as detection agent. HEL-specific Ig was measured after
seven days culture by ELISA employing HEL (1 mg/ml) as capture
antigen and 2 mg/ml biotinylated anti-mouse IgM
a (clone DS1) as
detection mAb. To determine HEL-specific Ig in vivo, blood was
obtained from six to ten week old, naı ¨ve IgHELTg and IgHEL/
CD83 double Tg mice by puncture of the tail vein. After 60 min
coagulation at room temperature serum was harvested by
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HEL-specific Ig by ELISA.
Monitoring of intracellular [Ca
2+]
UntouchedBandTcellswerepurifiedfromC57BL/6andCD83Tg
mice by magnetic cell sorting employing Pan-B cell and Pan-T cells
isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and
loaded with Fura-2-AM as described [23]. In brief, 3610
7 cells were
centrifuged at 1500 rpm for 5 min and suspended in 1 ml RPMI
1640 (supplemented with 10% FCS, L-Glutamine; 20 mM Hepes)
at 37uC. After an incubation period of 5 min at 37uC, Fura-2
acetoxymethylester (fura-2-AM), the membrane-permeant form of
Fura-2, was added to the cells at a final concentration of 4 mg/ml.
After a 15 min incubation period, the cell suspension was diluted 5-
fold with warm RPMI 1640 and again incubated for 15 min at
37uC.Nextthecellswerewashedandresuspendedataconcentration
of 6610
6 cells per ml in a buffer containing 140 mM NaCl, 5 mM
KCl, 1 mM MgSO4, 1 mM CaCl2,2 0 m MH E P E S ,1 m M
NaH2PO4, 5.5 mM glucose, pH 7.4. For [Ca
2+]i monitoring
500 ml cell suspension and 500 mlb u f f e rw e r et r a n s f e r r e di n t o
a fluorimeter cuvette. [Ca
2+]i was monitored at room temperature in
a Hitachi F-2000 fluorometer at excitation wavelengths of 340/
380 nm (alternating) and an emission wavelength of 495 nm. A
stable baseline was generated after approximately 150 s, the
stimulant anti-BCR (LO-MK) for purified B cells or anti-CD3
(145-2C11) for purified T cells was added at a concentration of
10 mg/mland [Ca
2+]iwasmonitoredforanother10 min.Attheend
of each measurement the maximal fluorescence (Fmax) was de-
termined by addition of Triton X-100 (10% v/v final concentration)
and the minimal fluorescence (Fmin) was determined by addition of
EGTA/Tris (400 mM EGTA, 3 M Tris, pH 7.4).
RESULTS
CD83 is rapidly upregulated on activated B cells in
vitro
During the course of an ongoing infection with Leishmania major,B
cells are the dominant CD83 positive cell population and surface
expression of CD83 on B cells is strictly correlated with the site
and the kinetics of infection [21]. In order to investigate the
kinetics of CD83 expression after activation of B cells, we
stimulated total spleen cells in vitro either with anti-BCR,
a combination of anti-BCR and IL-4 or with LPS. Figure 1A
shows that surface CD83 expression occurred three hours post
stimulation of spleen cells predominantly on CD19 positive B cells.
The CD83 staining on activated B cells was successfully competed
by pre-incubation with unlabeled anti-CD83 mAb or with
a CD83Ig fusion protein but not with CD28Ig fusion protein
(data not shown). CD83 expression on B cells reached a maximum
at six hours post stimulation in cultures stimulated via BCR- or
TLR-engagement. While both stimuli induced CD83 upregulation
with comparable kinetics, the different nature of the stimuli
employed was reflected by differences in the survival of spleen cells
at later time points of culture (figure 1A), in the maximum
percentage of CD83 positive B cells (figure 1B) and in the intensity
of CD83 surface expression (figure 1C). Stimulation with LPS
rendered more than 90% of the B cells positive for CD83 six hours
after stimulation and induced sustained CD83 surface expression
for five days. The engagement of the BCR in the absence of
further stimuli however, activated only 30% of the splenic B cells
to express CD83 and spleen cells died after two days of in vitro
culture. Costimulation with IL-4 (figure 1A) or anti-CD40 mAb
(data not shown) induced increased and prolonged CD83
expression on B cells as well as prolonged viability of cultures.
In order to analyze if CD83 was specifically expressed on
activated B cells in the spleen cell culture, we measured the
correlation between CD83 expression and the early activation
marker CD69. Figure 1D shows that CD83 expression preceded
CD69 expression. While 23% B cells were double positive for
CD69 and CD83 at three hours post LPS stimulation, 47% B cells
already expressed surface CD83 but still were negative for CD69.
CD69 was further upregulated and six hours post LPS stimulation
90% of splenic B cells became double positive for CD83 and
CD69. After 24 hours of stimulation, expression of CD83
decreased and CD69 positive CD83 negative B cells occurred
for the first time. Stimulation of splenic B cells with anti-BCR and
anti-CD40 mAb led to similar results (data not shown).
It has been shown that surface expression of human CD83 upon
DCmaturation ispartiallymediated bythetransportofintracellular
stored CD83 protein to the plasma membrane [24,25]. To visualize
intracellular CD83 in murine B cells, we performed western blots
with purified C57BL/6 derived B cells, employing a polyclonal
rabbit anti-mouse CD83 antiserum. Hereby CD83 protein
migrated in a broad and faint band ranging from 40 kD to 60 kD
(data not shown). This was due to different glycosylation of the
CD83 protein present in the lysates since deglycosylation changed
the CD83 protein migration pattern to a distinct band at
approximately 20 kD (figure 1E), which is in line with the predicted
molecular weight for a protein consisting of 175 amino acids [5,6].
Strikingly, no CD83 protein was detectable in lysates of naı ¨ve B cell
cultures whereas increasing amounts of CD83 protein were present
in lysates of B cells that had been LPS activated for one or six hours
respectively (figure 1E). This result suggests that activated B cells
express CD83 by de novo protein synthesis.
CD83 expression modulates MHC-II and CD86
surface expression on B cells
In order to investigate a possible impact of activation-induced
CD83 on B cell function in vitro, we employed mouse strains with
manipulated CD83 expression levels. CD83Tg mice (CD83Tg
founder 2 and CD83Tg founder 1) overexpress murine CD83
under the control of a MHC-I promoter on every nucleated cell in
vivo [20]. CD83mu mice (originally named LCD4.1) carry
a missense mutation in the stop codon of the CD83 gene leading
to a 55 amino acid extension, thus resulting in a severe reduction
of CD83 protein expression [8].
First we compared expression of different activation markers on
B cells derived from wild-type, CD83Tg or CD83mu mice. B cells
within whole spleen cell cultures were analyzed for CD83, CD86,
CD80, CD69, CD40, MHC-II and surface IgM expression either
ex vivo or after two days of cultivation in the presence of LPS. As
expected, given our previous findings, LPS stimulation induced
upregulation of CD83 on wild-type B cells (figure 2A, open bars,
either C57BL/6 or CD83 negative littermate to CD83Tg founder
1). CD83Tg B cells displayed an increased CD83 expression on
naı ¨ve as well as on LPS activated B cells. The observed CD83
upregulation on LPS activated CD83Tg B cells can be due to both
endogenous CD83 expression as well as induction of MHC-I
promoter controlled transgenic expression of the CD83 transgen.
Naı ¨ve CD83mu mice in contrast, displayed no detectable CD83
and activation-induced CD83 upregulation was drastically re-
duced (figure 2A). Interestingly CD83 overexpression led to
a significantly increased expression of MHC-II and of the
costimulatory receptor CD86 on both naı ¨ve and LPS activated
B cells while the diminished CD83 expression on CD83mu B cells
was correlated to a reciprocally reduced expression of MHC-II
and CD86 (figure 2B, 2C). This did not reflect a generalized
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PLoS ONE | www.plosone.org 3 August 2007 | Issue 8 | e755Figure 1. CD83 is upregulated on activated B cells. C57BL/6 mice derived spleen cells (2610
6/ml) were stimulated with anti-BCR (1 mg/ml) and IL-4
(20 ng/ml) or with LPS (10 mg/ml) as indicated in the headline. Cells were triple stained for CD19, CD83 and CD69 at the indicated time points. 1A:
Dot blots show all lymphocytes positive for surface expression of CD83 on the x-axis and CD19 expression on the y-axis. 1BC: Graphs show the
percentage of CD83 positive B cells (1B) or the mean fluorescence intensity (MFI) of CD83 on B cells (1C) after stimulation with anti-BCR alone (open
circle) anti-BCR and IL-4 (closed circle) or with LPS (closed square) in an independent experiment, error bars show SEM of duplicates. 1D: Dot blot
shows 2610
4 CD19 positive cells derived from LPS activated spleen cells analyzed for CD83 (x-axis) and CD69 (y-axis) surface expression. 1E: 2610
6
purified C57BL/6 spleen derived B cells were stimulated with LPS (10 mg/ml). B cells were lysed at the indicated time points, deglycosylated and
separated by SDS-PAGE. CD83 was detected by western blot with a polyclonal rabbit anti-CD83 serum. Results are representative for at least three
independent experiments.
doi:10.1371/journal.pone.0000755.g001
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PLoS ONE | www.plosone.org 4 August 2007 | Issue 8 | e755Figure 2. Positive correlation of CD83 expression to CD86 and MHC-II expression on CD83Tg and CD83mu B cells. C57BL/6 and CD83 negative
littermates to CD83Tg founder 1 mice (open bars), CD83Tg (black bars) or CD83mu (dark grey bars) derived spleen cells (2610
6/ml) were double
stained for CD19 and either CD83 (2A), CD86 (2B), MHC-II (2C), CD80 (2D), CD40 (2E), CD69 (2F) or IgM (2G) ex vivo or after 48 h incubation with
10 mg/ml LPS as indicated on the x axis. 2610
4 CD19 positive cells were analyzed by FACScan. Please note that each bar represents the combined
results of five independent experiments employing two female age matched mice of each group per experiment, error bars show SEM. Asterisks
indicate a significant difference of the mean (* p,0.05; ** p,0.005; *** p,0.0005) employing students t test.
doi:10.1371/journal.pone.0000755.g002
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respectively, since the expression of the early activation marker
CD69, the costimulatory receptors CD80 and CD40 as well as
surface IgM were normal (figure 2D–2G). Repetition of these
experiments with CD83Tg mice derived from an independently
generated founder (founder 2) led to similar results (data not
shown). Furthermore, this result was reproduced employing
purified B cells (data not shown). Taken together these experi-
ments show that CD83 expression is positively correlated to CD86
and MHC-II expression on B cells.
CD83 overexpression modulates B cell function
in vitro
Toanalyzethe biologicalrelevanceofthe correlationbetween CD83
and MHC-II and CD86 expression, we compared proliferation, Ig
and cytokine secretionofCD83Tg, CD83muandwild-type B cells in
vitro. First, we assessed the responseof CD83Tg (founder 2) and wild-
typespleencellstoboth,TcellspecificandBcellspecificstimulation.
Proliferation upon LPS stimulation was slightly but non-significantly
reduced inCD83Tg spleen cells (figure 3A), while proliferation upon
CD3 engagementwascomparable thusdemonstrating normal T cell
function within CD83Tg spleen cell cultures (figure 3B). In vitro
secretion of LPS induced Ig, however, was significantly reduced in
CD83Tg spleen cells compared to C57BL/6 spleen cells (figure 3C)
indicating that transgenic expression of CD83 specifically interfered
with B cell function in vitro. The analysis of cytokines in the culture
supernatant revealed increased IL-10 secretion in LPS activated
CD83Tg spleen cell cultures compared to wild-type spleen cell
cultures (figure 3D), arguing against a generalized defect in CD83Tg
lymphocytes. Stimulation experiments employing spleen cells de-
rived from CD83Tg founder 1 mice led to similar results, thus ruling
Figure 3. CD83Tg spleen cells display reduced Ig and increased IL-10 response to LPS stimulation. 3A-D: 2610
5 spleen cells derived from sex and
age matched C57BL/6 (open squares) or CD83Tg founder 2 (closed squares) were cultured in the presence of LPS (10 mg/ml) or anti-CD3 (145-2C11,
1 mg/ml) or no further stimulus, as indicated on the x-axis. 3AB: Proliferation was estimated after 48h by
3H thymidine incorporation. 3C: Total mouse
Ig in the supernatant was measured after seven days by ELISA. Results are presented as relative ELISA units (REU: OD450 sample: OD450 medium
control) of a 1:1024 dilution. 3D: IL-10 in the supernatant was quantified by ELISA after 48 h. Each dot represents the analysis of an individual mouse
(mean of five replicates the SEM not shown, being below 10%). The lines indicate the median of all mice analyzed and the asterisks indicate
a significant difference of the median (*p,0.05; **p,0.005) employing students t test. 3E: HEL-specific Ig in the serum of six IgHEL Tg mice (open bar)
or six IgHEL CD83double Tg mice (black bar) was quantified by ELISA, error bars indicate SEM. 3F:2 610
5 spleen cells derived from six IgHEL Tg mice
(open bars) or from spleen cells derived from IgHEL CD83 double Tg mice (black bars) were cultivated in vitro for 48 h in the presence of indicated
amounts of LPS. HEL-specific Ig in the supernatant was quantified by ELISA and is presented as REU of a 1: 40 dilution. Error bars show SEM of five
replicates. This result is representative for five independent experiments.
doi:10.1371/journal.pone.0000755.g003
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phenotype of CD83Tg founder 2 spleen cells (data not shown).
To allow the precise analysis of antigen-specific Ig secretion in
vitro, we employed mice transgenic for a hen egg lysozyme-specific
BCR (IgHEL) [22] that were crossed to either C57BL/6 or
CD83Tg mice. Figure 3E shows that the amount of HEL-specific
Ig in the serum of untreated IgHEL6CD83Tg mice was dramati-
cally reduced compared to HEL-specific Ig in the serum of
IgHEL6C57BL/6 mice. In line with this finding, in vitro
stimulation of IgHEL6C57BL/6 and IgHEL6CD83Tg derived
spleen cells clearly revealed reduced production of HEL-specific Ig
by IgHEL6CD83Tg B cells compared to IgHEL6C57BL/6 B
cells (figure 3F). Neutralization of IL-10 did not change the
amount of HEL-specific Ig produced upon LPS activation,
suggesting that the increased amount of IL-10 present in the
CD83Tg spleen cell cultures was not the underlying cause of
reduced Ig secretion observed in our system (data not shown).
CD83 mediated modulation of B cell function is
independent of accessory cells
We have shown above that activated wild-type B cells rapidly
upregulate CD83 and that transgenic overexpression of CD83
modulates B cell function within spleen cell cultures in vitro. Since
CD83 is expressed under the control of the MHC-I promoter [20],
it is possible that reduced Ig response and reciprocally increased
IL-10 response to LPS stimulation are due to expression of CD83
by cells other than B cells. To further analyze whether the
premature CD83 expression on B cells themselves modulates their
own function, we stimulated purified B cells from C57BL/6 and
CD83Tg mice in vitro. This allowed us to compare the behavior of
wild-type B cells that start to upregulate CD83 three hours post
stimulation to B cells that overexpress CD83 already at the
beginning of stimulation. Figure 4 shows that the slightly reduced
proliferation, the significantly reduced Ig secretion as well as the
significantly increased IL-10 response observed in whole spleen
cells (figure 3A, 3C, 3D) were also visible in purified B cell cultures
(Figure 4). Stimulation of CD83Tg B cells with a combination of
anti-BCR and IL-4 or with anti-BCR/anti-CD40 revealed similar
results regarding proliferation while cytokine and Ig secretion were
not observed at all employing these stimuli (data not shown).
Reduced proliferation as well as increased IL-10 secretion in
purified CD83Tg B cells were visible from day one through day
five of a time course experiment thus ruling out a shift of
proliferation or cytokine secretion maximum (data not shown).
These results show that the increased amount of LPS-induced IL-
10 was produced by the B cells themselves and that the altered
function of CD83Tg splenic B cells was not dependent on CD83
expressed on accessory cells. Furthermore, these results shows that
the reduced amount of Ig produced by CD83Tg spleen cell
cultures does not merely reflect the slightly reduced amount of B
cells within CD83Tg spleens [21]. In contrast the increase in LPS
induced IL-10 secretion as well as the reduction in LPS-induced Ig
secretion were even more pronounced in purified B cell cultures
(figure 4B, 4C: p=0.0001 and p,0.0006) compared to whole
spleen cell cultures (figure 3C, 3D: p=0.0032 and p=0.018).
In vitro stimulation of CD83mu spleen cells
Having shown that CD83 overexpression induced an increased
IL-10 and reciprocally decreased Ig secretion by both CD83Tg
spleen cells and purified B cells we next asked whether reduced
CD83 expression would lead to an inverse phenotype. Compar-
ison of LPS induced proliferation (figure 5A), Ig secretion
(figure 5B) and IL-10 secretion (figure 5C) however, revealed no
significant difference between CD83mu and wild type spleen cells
despite their significantly decreased expression of MHC-II and
CD86 (figure 2B, 2C). Stimulation of T cells by CD3 engagement
on the other hand, induced reduced proliferation (figure 5D) and
drastically reduced IL-2 secretion (figure 5E) by CD83mu spleen
cells, which is in concordance with the described defective thymic
maturation of CD4+ T cells in these mice [8].
Further analysis of purified CD83mu B cells, however, revealed
a slight increase in Ig secretion (figure 6A) correlated to
a significantly reduced IL-10 secretion (figure 6B) by B cells
derived from CD83mu mice. Although the reciprocal increase in
IL-10 secretion together with the significantly reduced Ig secretion
in CD83Tg derived B cells (figure 6A, 6B black bars) is more
pronounced than the inverse phenotype of CD83mu B cells, this
Figure 4. Purified CD83Tg B cells display reduced Ig and increased
IL-10 response to LPS stimulation. Untouched B cells were isolated
from pooled spleens of two 8–10 week old sex matched C57BL/6 (open
squares) and CD83Tg (black squares) mice. 2610
5 B cells were cultured
in 5 replicates in the presence of LPS (10 mg/ml) or no further stimulus,
as indicated on the x-axis. Proliferation (4A) or IL-10 secretion (4B) were
measured after 48h. 4C: Total mouse Ig in the supernatant (dilution
1:1024) was measured after seven days by ELISA. Each dot represents an
individual experiment, employing B cells purified from two pooled
spleens (mean of five replicates the SEM not shown, being below 10%).
The bars indicate the median and the asterisks indicate a significant
difference of the median (***p,0.0005), employing students t test.
doi:10.1371/journal.pone.0000755.g004
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correlated to IL-10 and negatively correlated to Ig secretion.
Overexpression of CD83 on B cells interferes with
calcium signaling
While proliferation and secretion of cytokines and Ig are the final
consequences of a productive B cell activation one of the earliest
events is the increase in the free cytosolic calcium concentration
([Ca
2+] i) within seconds after BCR ligation. Therefore, we
compared the Ca
2+ signaling in purified C57BL/6 and CD83Tg B
cells and, as a specificity control, in purified T cells. Figure 7A
shows that the peak Ca
2+ signal upon BCR engagement was
significantly reduced in CD83Tg B cells compared to C57BL/6 B
cells (figure 7A, 7B). In contrast, TCR engagement induced
comparable Ca
2+ signaling in T cells purified from wild type and
CD83Tg mice (figure 7C, 7D). These results show that transgenic
overexpression of CD83 does not interfere with Ca
2+ signaling in
general, but selectively with the Ca
2+ signaling induced by BCR
engagement. The fact that the impaired Ca
2+signaling was
observed in purified B cell cultures in the absence of other
CD83Tg cells again demonstrates that premature CD83 expres-
sion on B cells themselves interferes with very early events
specifically in B cell activation.
DISCUSSION
Recently, we reported a novel function for murine CD83. Next to
its well established role in the thymic maturation of T helper cells
and in the regulation of peripheral T cell responses, we provided
evidence that CD83 was also involved in the regulation of B cell
function in vivo since i) CD83 was upregulated on activated B cells
in vivo, ii) premature transgenic CD83 surface expression on the B
cells themselves interfered with Ig response to TI and TD model
antigen immunization and iii) CD83Tg mice displayed a dramat-
ically reduced B cell response to L. major infection while mounting
an unchanged protective T cell response and iv) in vivo application
of anti-CD83 mAb induced a ten-fold increase in antigen specific
IgG1 upon TI-2 model antigen immunization [21]. In the present
Figure 5. In vitro stimulation of CD83mu spleen cells. 2610
5 spleen cells derived from C57BL/6 (open squares) or CD83mu (closed circles) mice were
cultured in the presence or absence of LPS (1 mg/ml) as indicated on the x-axis. 5A: Proliferation was estimated by
3H thymidine incorporation after
48h culture. 5B: Total mouse Ig in the supernatant was measured after seven days by ELISA and results are presented as REU of a 1:200 dilution. 5C:
IL-10 in the supernatant was quantified by ELISA after 48 h. 5DE: spleen cells were cultured in the presence or absence of anti-CD3 (1 mg/ml).
Proliferation (5D) and IL-2 secretion (5E) were measured after 48h culture. Each dot represents an individual experiment performed in five replicates
SD being below 10%, the bars indicate the median of all five experiments performed.
doi:10.1371/journal.pone.0000755.g005
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modulation of B cell activation and B cell function in vitro.
In concordance with the inflammation-induced upregulation of
CD83 demonstrated for B cells in vivo, CD83 was also upregulated
on in vitro activated B cells. CD83 expression was induced with
similar kinetics albeit different intensity either via TLR engage-
ment or via BCR engagement and therefore is a consequence of
both: innate and adaptive B cell activation. In line with these
findings human CD83 transcription was shown to be regulated by
NFkb [26,27], a transcription factor that is induced as a conse-
quence of either TLR or BCR signaling. We argue that the CD83
positive B cell population represents activated B cells within the
spleencellculture, sincewe didnot detectB cells expressing the early
activation marker CD69 withoutbeing alsopositive for CD83 within
the first 12 hours of stimulation. Surface expression of CD83 on
humanDCwasshowntobemediatedbymembranetranslocationof
the protein from intracellular stores [24] as well as by accumulation
of an otherwise recirculating CD83 pool on the plasma membrane
[25]. Nevertheless and despite the rapid kinetics of upregulation we
did not detect significant intracellular CD83 protein stores in resting
murine B cells, arguing in favor of a de novo CD83 protein synthesis
in activated murine B cells. Concurring with our results CD83
upregulation by maturing human DC was shown to be also
mediated by de novo protein synthesis [28].
In line with the defective humoral response and intact T cell
response observed inCD83Tgmiceinvivo [21]transgenicexpression
of CD83 resulted in a significant reduction of Ig secretion in vitro
while the T cell proliferation was normal. Furthermore, as shown in
vivo, the reduced Ig secretion of CD83Tg B cells in vitro was mediated
by CD83 expression on the B cells themselves and not by accessory
CD83Tg cells. Analyzing early signal transduction events we show
that already the peak calcium signal after BCR ligation was
significantly reduced in purified CD83Tg B cells. Again, this did not
reflect a generalized defect in cellular calcium handling since TCR
engagement induced comparable Ca
2+ signaling in purified
CD83Tg and wild-type T cells.
Strikingly, overexpression of CD83 did not result in an overall
impaired function of CD83Tg B cell in vitro but induced
a qualitative change in the phenotype of activated B cells: purified
CD83Tg B cells were characterized by a significantly and
reproducibly increased IL-10 production upon LPS stimulation
in vitro. Although most of the pleiotropic functions IL-10 exhibits
are anti-inflammatory [29,30] IL-10 is regarded as a growth and
differentiation factor for B cells [31,32]. We consider it unlikely
that the increased amount of IL-10 present in the CD83Tg B cell
cultures caused the phenotype observed in vitro, since neutraliza-
tion of IL-10 did not affect Ig secretion by IgHEL Tg B cells.
Furthermore, the reduced calcium signaling observed in CD83Tg
B cells takes place within seconds after BCR engagement i.e. well
before the increased IL-10 concentration could affect B cell
function. Therefore our data suggest that the increased IL-10
secretion observed in CD83Tg B cells is one feature but not the
mediator of their altered phenotype. Future investigation will
analyze a possible impact of increased IL-10 production by
CD83Tg B cells in vivo, especially if CD83Tg B cells share features
with IL-10 producing regulatory B cells [33–35] that have been
described to be beneficial in various autoimmune disease models
such as the recovery from EAE in resistant B6 mice [36].
Reporting a defective Ig response of CD83Tg B cells in vivo [21]
we suggested that CD83 might represent an additional regulatory
receptor such as CD22 [37] and CD72 [38] that is upregulated
upon B cell activation and contributes to the regulatory
mechanisms that prevent overstimulation of the B cell population
[39]. The interference of premature CD83 expression with early
signal transduction events upon BCR engagement as well as the
decreased Ig secretion and increased IL-10 secretion of CD83Tg B
cells in vitro, that we describe within this study, strongly support our
hypothesis. The fact that CD83
2/2 mice did not display an
increased Ig response to DNP-KLH in vivo [7] as could be expected
from mice lacking a putative negative B cell regulator does not
contradict our hypothesis, since it can be explained by the reduced
amount of CD4-positive T cells in these mice, as the Ig response to
DNP-KLH depends on T cell help. We are currently analyzing in
vivo B cell responses of CD83mu B cells in wild-type/CD83mu
bone marrow chimeras that display a normal T cell population
due to T cell maturation on wild-type thymic epithelium.
B cells derived from CD83
2/2 mice however, were also reported
to display reduced MHC-II and CD86 upregulation upon in vitro
activation [7]. These findings apparently contradict our hypothesis,
since here CD83
2/2 B cells themselves seem to display an impaired
rather than an activated phenotype. Analyzing LPS activated
CD83mu B cells we, within this study, reproduced the impaired
MHC-II and CD86 expression shown for CD83
2/2 Bc e l l s .
Interestingly our results clearly show that decreased activation
marker expression on CD83mu B cells was not correlated to
impaired B cell function since proliferation was normal and Ig
secretion by LPS activated purified CD83mu B cells was even
slightly increased. We also demonstrate that an increase in CD83
Figure 6. Reduced IL-10 secretion by CD83mu B cells. Untouched B
cells were isolated from pooled spleens of two 8–10 week old sex
matched C57BL/6 (open bars), CD83Tg (black bars) and CD83mu (dark
grey bars) mice. 2610
5 B cells were cultured in triplicates in the
presence of titrated amounts of LPS as indicated on the x-axis. 6A: Total
mouse Ig in the supernatant (dilution 1:1024) was measured after seven
days by ELISA. 6B: IL-10 in the supernatant was measured after 48 h.
Presented are the combined results of 3 independent experiments,
error bars show SEM. Asterisks indicate a significant difference of the
mean (* p,0.05; ** p,0.005 *** p,0.0005) employing students t test.
doi:10.1371/journal.pone.0000755.g006
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CD86 on CD83Tg B cells that again was not correlated to an
increased activation state at least with respect to proliferation and Ig
secretion. Finally, expression of all other activation markers and
costimulatory receptors investigated was unchanged in CD83mu
andCD83TgBcells.Therefore,wearguethatthealteredCD86and
MHC-II surface expression observed in CD83mu and CD83Tg as
well as CD83
2/2 B cells does not reflect their activation state.
We recognize that although increased CD83 expression led to
a clearly reduced Ig and increased IL-10 secretion by CD83Tg
spleencellsand purified Bcells,reducedCD83expressioninpurified
CD83mu B cells only induced a slight increase in Ig and decrease in
IL-10 secretion respectively. This ‘‘weaker’’ phenotype may either
reflecttheredundancyofnegativeregulationinB cells[39]butcould
also be due to the low residual CD83 expression by the CD83mu B
cells employed. Analysis of CD83
2/2 B cells that are completely
devoid of CD83 protein [7], would answer this question.
Furthermore, employing non-conditional transgenic and mu-
tant models we cannot rule out the possibility that artificial CD83
overexpression or deficiency on pro- and pre-B cells or stromal
cells during B cell maturation within the CD83Tg and CD83mu
mice results in the generation of dysfunctional B cells. While the
bone marrow resident pre B cell compartment appears to be
normal in CD83Tg and CD83mu mice (Lu ¨thje et al., manuscript
in preparation) the increased proportion of transitional B cells
within CD83Tg spleens [21] indeed suggest interference with final
B cell maturation that may contribute to the phenotype. Since the
maturation of B cells also depends on intact BCR signaling, this
partial arrest in maturation of CD83 overexpressing B cells may
again reflect a possible CD83 mediated regulation.
Taken together the combined findings presented within this
manuscript that CD83Tg B cells displayed reduced Ig and increased
IL-10 secretion whereas CD83mu B cells that express diminished
amounts of CD83 displayed a slightly increased Ig and a decreased
IL-10 production further suggests that B cell response is modulated
by CD83 expression on B cells. Regarding the mechanism by which
CD83 may modulate B cell function, a direct negative regulation
through recruitment of Src-homology domain 2 containing proteins
is not possible since CD83 lacks an ITIM motif in its predicted
intracellular tail [1,5]. Nevertheless it is conceivable that CD83 is
involved in modulation of BCR signaling through association with
other signaling receptors as in the CD14/TLR4 system [40].
Alternatively our data do not exclude the possibility that the
interference with BCR activation is not transduced by CD83 but by
a putative CD83 ligand on B cells that is engaged by overexpressed
transgenic CD83. The identification of CD83 associated molecules
and putative CD83 ligands will contribute to the elucidation of
CD83 mediated regulation of B cell activation.
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Figure 7. Reduced calcium signaling in CD83Tg B cells. Untouched B (7AB) or T cells (7CD) were isolated from pooled spleens of two 8–10 week old
sex matched C57BL/6 (open bars) and CD83Tg (black bars) mice. Purified B and T cells were loaded with Fura-2-AM and stimulated with anti-BCR (Lo-
MK) or anti-CD3 (145-2C11) respectively (10 mg/ml each). [Ca
2+]i was calculated from the fluorescence intensity ratio at 340 and 380 nm. 7AC: Bars
represent the combined results from nine independent measurements, error bars show SEM. Asterisks indicate a significant difference of the mean.
7BD: Shown is a characteristic calcium tracing from a single experiment for B cells (7B) and T cells (7D) obtained from C57BL/6 (solid line) or CD83Tg
(dotted line) mice.
doi:10.1371/journal.pone.0000755.g007
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